Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when RANI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRani Therapeutics reports Q4 and full-year 2025 financial results
Filed March 26, 2026 · Period ending March 26, 2026 · ~1 min read
Key Changes
-
high
Company issued press release with fourth quarter and full-year 2025 financial results plus corporate update on March 26, 2026. Specific financial figures and operational metrics are in the attached press release.
Item 7.01 view on EDGAR → -
medium
The 8-K filing itself contains no financial details or forward guidance—all substantive information is in Exhibit 99.1, which requires separate review to assess company performance.
Exhibit 99.1 view on EDGAR →
Summary
Rani Therapeutics filed an 8-K on March 26, 2026 to announce its fourth quarter and full-year 2025 financial results. The filing is a standard earnings disclosure vehicle, with the actual financial data, operational updates, and management commentary contained in an attached press release (Exhibit 99.1) rather than in the 8-K body text itself. Retail investors should review the press release exhibit to understand the company's financial performance, cash position, pipeline progress, and any forward-looking statements management provided.
As a clinical-stage biotech developing oral drug delivery technology, key metrics to watch include cash runway, partnership announcements, and clinical trial milestones. The next concrete item to monitor is whether the company files its full 10-K annual report on schedule, which will provide audited financials and detailed risk factor updates.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On March 26, 2026, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and year ended December 31, 2025.
The company disclosed its fourth quarter and full-year 2025 financial results along with a corporate update. The actual financial figures and operational details are contained in the press release (Exhibit 99.1), which is not included in this 8-K body text.
Event · Item 9.01 — Financial Statements and Exhibits
Rani Therapeutics filed an 8-K attaching a press release dated March 26, 2026; no material business event disclosed in the body.
Added in current filing · verify on EDGAR →
99.1
Press Release of Rani Therapeutics Holdings, Inc. dated March 26, 2026
The 8-K attaches a press release dated March 26, 2026 as Exhibit 99.1. The body of the 8-K provides no detail about the content of the press release, so the nature and materiality of the disclosure cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify